In the original publication [1], there was a mistake in Table 2 as published. The original Table 2 considered different amounts of patients for the survival analysis at the data cut-off. The corrected Table 2 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Table 2.
Univariate and multivariate analyses of factors associated with overall survival. XELIA: capecitabine and aromatase inhibitor; HT: hormone therapy (aromatase inhibitor); CTx: chemotherapy (capecitabine); ECOG PS: Eastern Cooperative Oncology Group Performance Status; SBR: Scarff–Bloom–Richardson; ER: estrogen receptor; PgR: progesterone receptor; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; BCS: breast conservation surgery; MRM: modified radical mastectomy; X: median not reached; * regardless of affected site. Statistically significant p-values are shown in bold.
| Total (Events) | Median (95% CI) | p-Value | HR (95% CI) | p-Value | |
|---|---|---|---|---|---|
| ECOG PS | 0.972 | ||||
| 0–1 | 136 (62) | 42.9 (31.1–54.7) | |||
| ≥2 | 27 (15) | 63.4 (33.9–92.8) | |||
| Hormonal status | 0.199 | ||||
| Pre- or peri-menopausal | 54 (19) | 46.5 (27.2–65.8) | |||
| Postmenopausal | 109 (58) | 52.3 (34.5–70.2) | |||
| Tumor status | 0.547 | ||||
| ≤T2 | 62 (25) | 62.4 (48.5–76.3) | |||
| T3 | 40 (21) | 40.9 (30.7–51.1) | |||
| T4 | 61 (31) | 41.8 (25.6–58.1) | |||
| Nodal status | 0.707 | ||||
| N0 | 24 (9) | 65.6 (29.7–101.4) | |||
| N1 | 59 (27) | 44.9 (36.7–53.2) | |||
| N2 | 51 (25) | 42.3 (33.4–51.1) | |||
| N3 | 29 (16) | 52.8 (25.7–79.9) | |||
| Disease state | 0.947 | ||||
| Recurrent disease | 131 (61) | 46.5 (33.1–60.0) | |||
| Metastatic disease | 32 (16) | 47.9 (16.2–79.7) | |||
| Histological subtype | 0.884 | ||||
| IDC | 135 (63) | 52.8 (35.5–70.1) | |||
| ILC | 28 (14) | 37.4 (26.4–48.3) | |||
| Ki67 | 0.507 | ||||
| <20 | 46 (17) | 62.39 (27.7–97.1) | |||
| ≥20 | 50 (24) | 46.5 (21.7–71.4) | |||
| Unknown | 67 (36) | 52.3 (32.2–72.5) | |||
| SBR | 0.085 | ||||
| Low | 13 (5) | 80.1 (31.7–128.6) | |||
| Intermediate and high | 130 (66) | 40.0 (34.3–47.5) | |||
| Unknown | 20 (6) | 63.4 (42.4–84.4) | |||
| ER | 0.451 | ||||
| Negative | 7 (4) | 18.1 (17.8–18.5) | |||
| Positive | 156 (73) | 47.9 (40.1–64.5) | |||
| PgR | 0.447 | ||||
| Negative | 32 (17) | 34.3 (11.5–57.3) | |||
| Positive | 131 (60) | 47.9 (28.1–67.8) | |||
| ER/PgR | 0.533 | ||||
| ER+, PgR+ | 124 (56) | 52.3 (32.6–72.1) | |||
| ER+, PgR− | 32 (17) | 34.4 (11.5–57.3) | |||
| ER−, PgR+ | 7 (4) | 18.1 (17.8–18.5) | |||
| Type of surgery | 0.387 | ||||
| BCS | 17 (5) | 98.9 (8.5–189.4) | |||
| MRM | 121 (61) | 44.9 (34.7–55.2) | |||
| None | 25 (11) | 36.3 (0–79.57) | |||
| Adjuvant endocrine Therapy | 0.748 | ||||
| Tamoxifen | 57 (26) | 52.3 (29.6–75.1) | |||
| Aromatase inhibitors | 106 (51) | 42.8 (26.9–58.8) | |||
| Disease-free interval % (n/N) | 0.993 | ||||
| Newly metastatic disease | 32 (16) | 47.9 (16.6–79.7) | |||
| ≤24 months | 40 (18) | 46.5 (24.3–68.7) | |||
| >24 months | 91 (43) | 44.9 (30.2–59.7) | |||
| Number of metastases % (n/N) | 0.010 | 1.129 (0.879–1.449) | 0.341 | ||
| 1 place | 105 (47) | 53.5 (34.9–72.1) | |||
| 2 places | 36 (22) | 34.4 (30.0–47.8) | |||
| ≥3 places | 12 (6) | 26.4 (9.5–43.3) | |||
| CNS involvement * | 10 (2) | X | |||
| Disease site % (n/N) | 0.068 | ||||
| Visceral | 84 (40) | 40.4 (21.4–59.4) | |||
| Non-visceral | 16 (3) | X | |||
| Bone | 63 (34) | 44.4 (37.3–52.6) | |||
| Treatment | 0.122 | 1.262 (0.947–1.683) | 0.112 | ||
| XELIA | 95 (45) | 53.5 (30.3–76.6) | |||
| Hormone therapy | 35 (15) | 47.9 (24.6–71.2) | |||
| Chemotherapy | 33 (17) | 40.4 (34.7–61.3) |
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Reference
- 1.Alvarado-Miranda A., Lara-Medina F.U., Muñoz-Montaño W.R., Zinser-Sierra J.W., Galeana P.A.C., Garza C.V., Sanchez Benitez D., Limón Rodríguez J.A., Arce Salinas C.H., Guijosa A., et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023;30:6097–6110. doi: 10.3390/curroncol30070454. [DOI] [PMC free article] [PubMed] [Google Scholar]